Ventzislav Stefanov compensation by year
Summit Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2020 |
|---|---|
| Salary | $290,718 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $277,508 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $106,597 |
| Total | $674,823 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Summit Therapeutics Inc. DEF 14A filed April 29, 2021, accession 0000921895-21-001172, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Summit Therapeutics Inc. filed document, accession 0000921895-21-001172. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2021.
Summit Therapeutics’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Michael Donaldson | Chief Financial Officer | $961,418 |
| Ventzislav Stefanov · this page | Former Executive Vice President, President of Discuva and Director (4) | $674,823 |
| Glyn Edwards | Former Chief Executive Officer and Director (4) | $621,822 |
| Mahkam Zanganeh | Director and Chief Operating Officer (3) | $527,312 |
| David Powell | Former Chief Scientific Officer | $401,124 |
| Robert Duggan | Chief Executive Officer and Executive Chairman (2) | — |
The full Summit Therapeutics compensation record
free company briefThis page is one person within Summit Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Summit Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.